YHB Investment Advisors Inc. cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,969 shares of the biopharmaceutical company’s stock after selling 1,041 shares during the period. YHB Investment Advisors Inc.’s holdings in Gilead Sciences were worth $1,932,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. Keel Point LLC lifted its holdings in Gilead Sciences by 0.4% in the second quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock valued at $221,000 after acquiring an additional 12 shares during the period. Paradigm Financial Advisors LLC lifted its holdings in Gilead Sciences by 0.3% in the second quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock valued at $617,000 after acquiring an additional 26 shares during the period. Princeton Portfolio Strategies Group LLC lifted its holdings in Gilead Sciences by 0.4% in the second quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock valued at $691,000 after acquiring an additional 41 shares during the period. Auxier Asset Management lifted its holdings in Gilead Sciences by 1.4% in the second quarter. Auxier Asset Management now owns 6,773 shares of the biopharmaceutical company’s stock valued at $479,000 after acquiring an additional 96 shares during the period. Finally, Edmonds Duncan Registered Investment Advisors LLC lifted its holdings in Gilead Sciences by 1.6% in the second quarter. Edmonds Duncan Registered Investment Advisors LLC now owns 6,386 shares of the biopharmaceutical company’s stock valued at $452,000 after acquiring an additional 100 shares during the period. 76.47% of the stock is currently owned by institutional investors.
A number of research firms have weighed in on GILD. Vetr downgraded Gilead Sciences from a “buy” rating to a “hold” rating and set a $91.25 target price on the stock. in a report on Monday, January 29th. Citigroup raised Gilead Sciences from a “neutral” rating to a “buy” rating and lowered their target price for the company from $88.80 to $76.00 in a report on Tuesday, January 30th. Morgan Stanley lowered their target price on Gilead Sciences from $87.00 to $84.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 7th. Bank of America increased their target price on Gilead Sciences from $82.00 to $87.00 and gave the company a “neutral” rating in a report on Wednesday, February 7th. Finally, BMO Capital Markets increased their target price on Gilead Sciences from $86.00 to $88.00 and gave the company a “market perform” rating in a report on Thursday, February 8th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $87.04.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.11. The company had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm’s quarterly revenue was down 18.7% on a year-over-year basis. During the same quarter last year, the company earned $2.70 EPS. equities analysts forecast that Gilead Sciences, Inc. will post 6.24 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be paid a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 2.83%. The ex-dividend date of this dividend is Thursday, March 15th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio (DPR) is 59.77%.
In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $74.64, for a total transaction of $1,119,600.00. Following the completion of the transaction, the executive vice president now owns 70,988 shares in the company, valued at approximately $5,298,544.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $74.98, for a total value of $5,498,508.34. Following the transaction, the insider now owns 3,070,099 shares of the company’s stock, valued at approximately $230,196,023.02. The disclosure for this sale can be found here. Insiders have sold a total of 418,333 shares of company stock worth $32,742,108 in the last three months. 1.30% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Gilead Sciences, Inc. (GILD) Position Lowered by YHB Investment Advisors Inc.” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://stocknewstimes.com/2018/02/18/gilead-sciences-inc-gild-position-lowered-by-yhb-investment-advisors-inc.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.